Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M., Blobe, G. C., Zafar, Y., … Hurwitz, H. (2016). Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). In Journal of Clinical Oncology (Vol. 34, pp. 3548–3548). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.3548

Strickler, John H., Christel N. Rushing, Hope Elizabeth Uronis, Michael Morse, Gerard C. Blobe, Yousuf Zafar, Shiaowen David Hsu, et al. “Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 34:3548–3548. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3548.

Strickler JH, Rushing CN, Uronis HE, Morse M, Blobe GC, Zafar Y, et al. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3548–3548.

Strickler, John H., et al. “Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 3548–3548. Crossref, doi:10.1200/jco.2016.34.15_suppl.3548.

Strickler JH, Rushing CN, Uronis HE, Morse M, Blobe GC, Zafar Y, Hsu SD, Arrowood C, Haley S, Dropkin E, Niedzwiecki D, Hurwitz H. Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3548–3548.